PortalPublikationenEvolving resistance landscape in gram-negative pathogens: An...

Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms

Standard

Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms. / König, Christina; Kuti, Joseph L.

in: PHARMACOTHERAPY, Jahrgang 44, Nr. 8, 08.2024, S. 658-674.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

König, C & Kuti, JL 2024, 'Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms', PHARMACOTHERAPY, Jg. 44, Nr. 8, S. 658-674. https://doi.org/10.1002/phar.2950

APA

König, C., & Kuti, J. L. (2024). Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms. PHARMACOTHERAPY, 44(8), 658-674. https://doi.org/10.1002/phar.2950

Vancouver

König C, Kuti JL. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms. PHARMACOTHERAPY. 2024 Aug;44(8):658-674. https://doi.org/10.1002/phar.2950

Bibtex

@article{33667e8c4bb44094865eb6b0d37f9ad1,
title = "Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms",
abstract = "Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β-lactamases diminishing the activity of classic β-lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β-lactamase inhibitors (BLIs) with activity against extended-spectrum β-lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo-β-lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem-resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β-lactamases including MBL and OXA-enzymes.",
author = "Christina K{\"o}nig and Kuti, {Joseph L.}",
year = "2024",
month = aug,
doi = "10.1002/phar.2950",
language = "English",
volume = "44",
pages = "658--674",
journal = "PHARMACOTHERAPY",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms

AU - König, Christina

AU - Kuti, Joseph L.

PY - 2024/8

Y1 - 2024/8

N2 - Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β-lactamases diminishing the activity of classic β-lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β-lactamase inhibitors (BLIs) with activity against extended-spectrum β-lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo-β-lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem-resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β-lactamases including MBL and OXA-enzymes.

AB - Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of β-lactamases diminishing the activity of classic β-lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of β-lactamase inhibitors (BLIs) with activity against extended-spectrum β-lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo-β-lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem-resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various β-lactamases including MBL and OXA-enzymes.

U2 - 10.1002/phar.2950

DO - 10.1002/phar.2950

M3 - SCORING: Review article

C2 - 38949413

VL - 44

SP - 658

EP - 674

JO - PHARMACOTHERAPY

JF - PHARMACOTHERAPY

SN - 0277-0008

IS - 8

ER -